and they could have given estimates showing that t

Quote:

---

and they could have given estimates showing that they didn't really cost us anything because the industry didn't like our once a week treatment with the blipping that Dr. J talked about.

---

The blipping is only a matter of consequence in monotherapy. Which is why the FDA suggested a combo therapy trial. With combo therapy you have ART controlling the blips and leronlimab stopping any HIV variants from arising. Unfortunately with Amarex screwing up the BLA other drugs came along which controlled for variants a bit better before we could get approval.